CIC Exam Dumps - CBIC Infection Control Questions and Answers

In a retrospective case-control study, cases and controls are selected based on disease status. The case group is composed of individuals who have the disease (cases), while the control group consists of individuals without the disease. This design allows researchers to look back in time to assess exposure to potential risk factors.

Step-by-Step Justification:

Selection of Cases and Controls:

Cases: Individuals who already have the disease.

Controls: Individuals without the disease but similar in other aspects.

Direction of Study:

A retrospective study moves backward from the disease outcome to investigate potential causes or risk factors​.

Data Collection:

Uses past medical records, interviews, and laboratory results to determine past exposures.

Common Use:

Useful for studying rare diseases since cases have already occurred, making it cost-effective compared to cohort studies.

Why Other Options Are Incorrect:

B. without the disease: (Incorrect) This describes the control group, not the case group.

C. with the risk factor under investigation: (Incorrect) Risk factors are identified after selecting cases and controls.

D. without the risk factor under investigation: (Incorrect) The study investigates whether cases had prior exposure, not whether they lacked a risk factor.

CBIC Infection Control References:

APIC Text, Chapter on Epidemiologic Study Design​.

The correct answer is A, "One dose of Tdap vaccine," as this is the recommended immunization for a 55-year-old nurse who received all childhood vaccinations. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, which align with recommendations from the Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP), adults who have completed a primary series of childhood vaccinations (typically 5 doses of DTaP or DTP) should receive a single booster dose of Tdap if they have not previously received it. This is especially critical for healthcare personnel, such as a 55-year-old nurse, due to their increased risk of exposure to pertussis and the need to protect vulnerable patients (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.2 - Implement measures to prevent transmission of infectious agents). The Tdap vaccine, which protects against tetanus, diphtheria, and pertussis, is recommended once between ages 11-64, with a preference for administration in early adulthood (e.g., 19-26 years) or as soon as feasible for older adults, including this 55-year-old nurse, to ensure immunity against pertussis, which wanes over time. For individuals aged 65 and older, Tdap is still recommended if not previously received, though Tdap is preferred over Td (tetanus and diphtheria only) for healthcare workers to address pertussis risk.

Option B (two doses of Tdap vaccine at least 14 days apart) and Option C (two doses of Tdap vaccine at least 28 days apart) are not standard recommendations for adults with a complete childhood vaccination history. Multiple doses are typically reserved for individuals with incomplete primary series or specific high-risk conditions, not for this scenario. Option D (no additional vaccination is recommended) is incorrect because, even with a complete childhood series, a Tdap booster is advised for healthcare workers to maintain protection, especially given the nurse’s occupational exposure risks (CDC Immunization Schedules, 2024). After receiving the Tdap booster, a Td booster every 10 years is recommended to maintain tetanus and diphtheria immunity, but the initial Tdap dose is the priority for this nurse.

The recommendation for one Tdap dose aligns with CBIC’s emphasis on evidence-based immunization policies to prevent transmission of vaccine-preventable diseases in healthcare settings (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.1 - Collaborate with organizational leaders). This ensures the nurse is protected and contributes to herd immunity, reducing the risk of pertussis outbreaks in the healthcare environment.

The correct answer is D, "A monitoring system must be in place following implementation of interventions," as this is essential to the quality improvement (QI) process. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, a key component of any QI initiative, such as studying the incidence of infections in patients with triple lumen catheters, is the continuous evaluation of interventions to assess their effectiveness and ensure sustained improvement. A monitoring system allows the infection preventionist (IP), Cancer Committee, and Intravenous Therapy Department to track infection rates, identify trends, and make data-driven adjustments to infection control practices post-intervention (CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competency 2.4 - Evaluate the effectiveness of infection prevention and control interventions). This step is critical to validate the success of implemented strategies, such as catheter care protocols, and to prevent healthcare-associated infections (HAIs).

Option A (establish subjective criteria for outcome measurement) is not ideal because QI processes rely on objective, measurable outcomes (e.g., infection rates per 1,000 catheter days) rather than subjective criteria to ensure reliability and reproducibility. Option B (recommendations for intervention must be approved by the governing board) is an important step for institutional support and resource allocation, but it is a preparatory action rather than an essential component of the ongoing QI process itself. Option C (study criteria must be approved monthly by the Cancer Committee) suggests an unnecessary administrative burden; while initial approval of study criteria is important, monthly re-approval is not a standard QI requirement unless mandated by specific policies, and it does not directly contribute to the improvement process.

The emphasis on a monitoring system aligns with CBIC’s focus on using surveillance data to guide and refine infection prevention efforts, ensuring that interventions for triple lumen catheter-related infections are effective and adaptable (CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competency 2.5 - Use data to guide infection prevention and control strategies). This approach supports a cycle of continuous improvement, which is foundational to reducing catheter-associated bloodstream infections (CABSI) in healthcare settings.

The Certification Study Guide (6th edition) identifies the use of maximum sterile barrier (MSB) precautions during central line insertion as a cornerstone practice for preventing intravascular device–associated infections, including central line–associated bloodstream infections (CLABSIs). MSB precautions include wearing a cap, mask, sterile gown, and sterile gloves, and using a large sterile drape to fully cover the patient during line insertion. These measures significantly reduce the risk of introducing skin flora and environmental microorganisms into the bloodstream at the time of catheter placement.

The study guide emphasizes that the highest risk for contamination occurs during insertion, making strict aseptic technique essential. MSB precautions are a required element of evidence-based central line insertion bundles and are consistently associated with reduced CLABSI rates when reliably implemented.

The other options reflect outdated or incorrect practices. Routine scheduled replacement of central lines every seven days is not recommended and does not reduce infection risk. The femoral vein is not the preferred insertion site in adults due to higher infection risk compared to subclavian or internal jugular sites. While alcohol is used during hub disinfection, chlorhexidine-based antisepsis (preferably chlorhexidine with alcohol) is recommended for skin preparation—not alcohol alone.

This question highlights a core CIC exam concept: standardized insertion practices using maximum sterile barriers are among the most effective strategies for preventing intravascular device infections.

The correct answer is A, "Observe all steps for reprocessing," as this is the most important process for the infection preventionist (IP) to review when evaluating a third-party reprocessor for single-use devices. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, the reprocessing of single-use devices (SUDs) by third-party entities must adhere to stringent infection control standards to ensure they are safe for reuse and do not contribute to healthcare-associated infections (HAIs). Observing all steps—such as cleaning, disinfection, sterilization, packaging, and quality control—allows the IP to directly assess compliance with manufacturer instructions, regulatory requirements (e.g., FDA guidelines), and best practices (e.g., AAMI ST91) (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.3 - Ensure safe reprocessing of medical equipment). This hands-on evaluation is critical because any deviation in the reprocessing chain can compromise device sterility and patient safety.

Option B (review the facility's blueprints and policies) provides context about the physical layout and procedural framework, but it is a preliminary step that does not directly verify the reprocessing process’s effectiveness. Option C (ensure air and water cultures are performed regularly) is important for monitoring environmental contamination risks, particularly in sterile processing areas, but it is a supportive measure rather than the primary focus of evaluating the reprocessor’s core activities. Option D (obtain feedback from other IPs who use the reprocessor) offers valuable peer insights, but it is subjective and secondary to direct observation, which provides firsthand evidence of compliance and performance.

The priority on observing reprocessing steps aligns with CBIC’s emphasis on ensuring the safety and efficacy of reprocessed medical devices, a key responsibility for IPs when outsourcing to third-party reprocessors (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.5 - Evaluate the environment for infection risks). This process enables the IP to identify specific weaknesses, validate adherence to standards, and make informed decisions about the reprocessor’s suitability.

The correct answer is C, "Toxic Anterior Segment Syndrome," as this is the inflammatory reaction that may occur in the eye after cataract surgery due to a breach in disinfection and sterilization of intraocular surgical instruments. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, Toxic Anterior Segment Syndrome (TASS) is a sterile, acute inflammatory reaction that can result from contaminants introduced during intraocular surgery, such as endotoxins, residues from improper cleaning, or chemical agents left on surgical instruments due to inadequate disinfection or sterilization processes (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.3 - Ensure safe reprocessing of medical equipment). TASS typically presents within 12-48 hours post-surgery with symptoms like pain, redness, and anterior chamber inflammation, and it is distinct from infectious causes because it is not microbial in origin. A breach in reprocessing protocols, such as failure to remove detergents or improper sterilization, is a known risk factor, making it highly relevant to infection prevention efforts in surgical settings.

Option A (endophthalmitis) is an infectious inflammation of the internal eye structures, often caused by bacterial or fungal contamination, which can also result from poor sterilization but is distinguished from TASS by its infectious nature and longer onset (days to weeks). Option B (bacterial conjunctivitis) affects the conjunctiva and is typically a surface infection unrelated to intraocular surgery or sterilization breaches of surgical instruments. Option D (toxic posterior segment syndrome) is not a recognized clinical entity in the context of cataract surgery; inflammation in the posterior segment is more commonly associated with infectious endophthalmitis or other conditions, not specifically linked to reprocessing failures.

The focus on TASS aligns with CBIC’s emphasis on ensuring safe reprocessing to prevent adverse outcomes in surgical patients, highlighting the need for rigorous infection control measures (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.5 - Evaluate the environment for infection risks). This is supported by CDC and American Academy of Ophthalmology guidelines, which identify TASS as a preventable complication linked to reprocessing errors (CDC Guidelines for Disinfection and Sterilization, 2019; AAO TASS Task Force Report, 2017).

The CBIC Certified Infection Control Exam Study Guide (6th edition) emphasizes that successful implementation of infection prevention recommendations depends on effective communication, engagement, and education tailored to the audience. Healthcare departments differ significantly in workflow, patient population, risk profile, and daily practices. Therefore, providing targeted, understandable education to staff is the most effective strategy to ensure recommendations are adopted and sustained.

Option A reflects best practice by aligning infection prevention guidance with the specific roles and responsibilities of staff in each department. Education that uses relevant examples, scenarios, and language improves comprehension, promotes buy-in, and supports behavior change. The Study Guide highlights that adult learners benefit most from education that is practical, interactive, and clearly applicable to their work environment.

Options B and C are ineffective because generic or non-customized approaches often fail to address department-specific challenges and may lead to confusion or poor compliance. Avoiding department-specific training ignores variations in risk and undermines accountability. Option D relies solely on enforcement rather than collaboration, which can result in resistance and decreased adherence.

For the CIC® exam, this question reinforces that infection prevention programs function best when they act as educators and partners, not just policy enforcers. Tailored education empowers staff, enhances compliance, and ultimately improves patient safety outcomes across diverse healthcare settings.

When a positive biological indicator (BI) is detected, the immediate response is to retest the sterilizer using another BI to confirm results. This helps distinguish between a true sterilization failure and a defective BI.

The CBIC Study Guide advises:

“If there is no indication of abnormalities, then the sterilizer should be tested again in three consecutive cycles using paired biological indicators from different manufacturers.”

Immediate recall is reserved for implant loads or confirmed sterilization failure.

Incorrect responses:

A. Check employee technique may be appropriate later but not as a first step.

B. Informing risk manager or C. Notifying patients occurs only after confirmation of failure.

The correct answer is D, "sodium hypochlorite," as it is an effective sporicidal disinfectant for Clostridioides difficile that the infection preventionist (IP) should recommend. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, Clostridioides difficile (C. difficile) is a spore-forming bacterium responsible for significant healthcare-associated infections (HAIs), and its spores are highly resistant to many common disinfectants. Sodium hypochlorite (bleach) is recognized by the Centers for Disease Control and Prevention (CDC) and the Environmental Protection Agency (EPA) as a sporicidal agent capable of inactivating C. difficile spores when used at appropriate concentrations (e.g., 1:10 dilution of household bleach) and with the recommended contact time (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.4 - Implement environmental cleaning and disinfection protocols). This makes it a preferred choice for environmental disinfection in outbreak settings or areas with known C. difficile contamination.

Option A (quaternary ammonium compound) is effective against many bacteria and viruses but lacks sufficient sporicidal activity against C. difficile spores, rendering it inadequate for this purpose. Option B (phenolic) has broad-spectrum antimicrobial properties but is not reliably sporicidal and is less effective against C. difficile spores compared to sodium hypochlorite. Option C (isopropyl alcohol) is useful for disinfecting surfaces and killing some pathogens, but it is not sporicidal and evaporates quickly, making it ineffective against C. difficile spores.

The IP’s recommendation of sodium hypochlorite aligns with CBIC’s emphasis on selecting disinfectants based on their efficacy against specific pathogens and adherence to evidence-based guidelines (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.5 - Evaluate the environment for infection risks). Proper use, including correct dilution and contact time, is critical to ensure effectiveness, and the IP should collaborate with the Product Evaluation Committee to ensure implementation aligns with safety and regulatory standards (CDC Guidelines for Environmental Infection Control in Healthcare Facilities, 2019).

Surgical wounds are classified by the Centers for Disease Control and Prevention (CDC) into four classes based on the degree of contamination and the likelihood of postoperative infection. This classification system, detailed in the CDC’s Guidelines for Prevention of Surgical Site Infections (1999), is a cornerstone of infection prevention and control, aligning with the Certification Board of Infection Control and Epidemiology (CBIC) standards in the "Prevention and Control of Infectious Diseases" domain. The classes are as follows:

Class I (Clean): Uninfected operative wounds with no inflammation, typically closed primarily, and not involving the respiratory, alimentary, genital, or urinary tracts.

Class II (Clean-Contaminated): Operative wounds with controlled entry into a sterile or minimally contaminated tract (e.g., biliary or gastrointestinal), with no significant spillage or infection present.

Class III (Contaminated): Open, fresh wounds with significant spillage (e.g., from a perforated viscus) or major breaks in sterile technique.

Class IV (Dirty-Infected): Old traumatic wounds with retained devitalized tissue or existing clinical infection.

Option A, "Incisions in which acute, nonpurulent inflammation are seen," aligns with a Class II surgical wound. The presence of acute, nonpurulent inflammation suggests a controlled inflammatory response without overt infection, which can occur in clean-contaminated cases where a sterile tract (e.g., during elective gastrointestinal surgery) is entered under controlled conditions. The CDC defines Class II wounds as those involving minor contamination without significant spillage or infection, and nonpurulent inflammation fits this category, often seen in early postoperative monitoring.

Option B, "Incisional wounds following nonpenetrating (blunt) trauma," does not fit the Class II definition. These wounds are typically classified based on the trauma context and are more likely to be considered contaminated (Class III) or dirty (Class IV) if there is tissue damage or delayed treatment, rather than clean-contaminated. Option C, "Incisions involving the biliary tract, appendix, vagina, and oropharynx," describes anatomical sites that, when surgically accessed, often fall into Class II if the procedure is elective and controlled (e.g., cholecystectomy), but the phrasing suggests a general category rather than a specific wound state with inflammation, making it less precise for Class II. Option D, "Old traumatic wounds with retained devitalized tissue," clearly corresponds to Class IV (dirty-infected) due to the presence of necrotic tissue and potential existing infection, which is inconsistent with Class II.

The CBIC Practice Analysis (2022) emphasizes the importance of accurate wound classification for implementing appropriate infection prevention measures, such as antibiotic prophylaxis or sterile technique adjustments. The CDC guidelines further specify that Class II wounds may require tailored interventions based on the observed inflammatory response, supporting Option A as the correct answer. Note that the phrasing in Option A contains a minor grammatical error ("inflammation are seen" should be "inflammation is seen"), but this does not alter the clinical intent or classification.